Related Experiment Video
Updated: Jun 16, 2026

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome
Published on: September 13, 2020
Treatment for thoracic outlet syndrome
Bo Povlsen1, Allan Belzberg, Thomas Hansson
1Department of Orthopaedics, Guy's and St Thomas' Hospitals NHS Trust, St Thomas Street, London, UK, SE1.
Evidence for thoracic outlet syndrome (TOS) treatments is limited. One study suggests transaxillary first rib resection may reduce pain more than supraclavicular neuroplasty, but more research is needed.
Area of Science:
- Neurology
- Vascular Surgery
- Orthopedic Surgery
Background:
- Thoracic outlet syndrome (TOS) is a clinically controversial condition.
- Evidence-based management is lacking despite numerous reported interventions.
Purpose of the Study:
- To evaluate the efficacy and safety of operative and non-operative treatments for TOS.
- To synthesize available scientific evidence for TOS interventions.
Main Methods:
- Systematic search of multiple databases (Cochrane, MEDLINE, EMBASE, CINAHL, AMED) up to June 2009.
- Inclusion of randomized or quasi-randomized studies for all TOS types (neurogenic, vascular, disputed).
- Primary outcome: pain reduction (visual analog scale) at six months; secondary outcomes: muscle strength and adverse effects.
Main Results:
- The review faced challenges due to a lack of standardized TOS diagnostic criteria.
- One high-risk-of-bias study (55 participants) indicated transaxillary first rib resection was superior to supraclavicular neuroplasty for pain reduction.
- No adverse effects were reported in the included trial; no studies compared interventions to natural progression.
Conclusions:
- A significant lack of high-quality evidence exists for TOS treatments due to diagnostic and methodological limitations.
- Very low-quality evidence suggests a potential benefit of transaxillary first rib resection over supraclavicular neuroplasty.
- There is an urgent need for agreed-upon diagnostic criteria, outcome measures, and high-quality randomized trials comparing interventions to each other and to no treatment.
Related Concept Videos
Angina IV: Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Coronary Artery Disease V: Interprofessional Care

